Old disease, new targets part-I, solid malignancies

Shiyam Kumar*, Nehal Masood, Asim Jamal Shaikh

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Targeted agents are now an integral part of treatment regimens for some cancers. Trastuzumab is established in treatment of human epidermal receptor 2 (Her2) positive breast cancers, with improvements in both, the disease free and over all survival. Monoclonal antibody (MoAB) against vascular growth factor receptor (VEGF), bevacizumab and cetuximab a MoAB against epidermal growth factor receptor (EGFR) are establishing their role in a many cancers after making their mark in colorectal cancer. Sorafenib and sunitinib have success stories in renal carcinoma. The Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial has established sorafenib role in advanced hepatocellular carcinoma, while in gastrointestinal tumors; imatinib and sunitinib have proven role. At this point in time side effect profile of all these agents appears relatively safe however cost for developing countries remains an issue.

Original languageEnglish
Pages (from-to)398-405
Number of pages8
JournalJournal of the Pakistan Medical Association
Volume59
Issue number6
Publication statusPublished - 2009

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Old disease, new targets part-I, solid malignancies'. Together they form a unique fingerprint.

  • Cite this